CompletedEarly Phase 1NCT01184885

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Principal Investigator
Margaret Kasner, MD
Thomas Jefferson University
Intervention
Hyper-CVAD(drug)
Enrollment
7 enrolled
Eligibility
18 years · All sexes
Timeline
20102013

Study locations (2)

Collaborators

American Society of Clinical Oncology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01184885 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials